4
Changes in Ownership
ACADIA PHARMACEUTICALS INC Filed Acc 0001209191-20-029858
CEO sold 200,000 shares at an average $46.02 ($9,204,692)
- CEO acquired 200,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| DAVIS STEPHEN CEO | 2020-05-13 | Option exercise | +111,458 | $19.65 | $2,190,150 | 123,267 | D |
| DAVIS STEPHEN CEO | 2020-05-13 | Sale | −13,908 | $48.98 | $681,244 | 109,359 | D |
| DAVIS STEPHEN CEO | 2020-05-13 | Sale | −5,205 | $48.60 | $252,953 | 104,154 | D |
| DAVIS STEPHEN CEO | 2020-05-13 | Sale | −20,756 | $46.43 | $963,705 | 83,398 | D |
| DAVIS STEPHEN CEO | 2020-05-13 | Sale | −63,392 | $45.71 | $2,897,858 | 20,006 | D |
| DAVIS STEPHEN CEO | 2020-05-13 | Sale | −8,197 | $45.12 | $369,827 | 11,809 | D |
| DAVIS STEPHEN CEO | 2020-05-14 | Option exercise | +88,542 | $19.65 | $1,739,850 | 100,351 | D |
| DAVIS STEPHEN CEO | 2020-05-14 | Sale | −84,221 | $45.65 | $3,844,596 | 16,130 | D |
| DAVIS STEPHEN CEO | 2020-05-14 | Sale | −4,321 | $45.01 | $194,509 | 11,809 | D |
| Derivatives | |||||||
| DAVIS STEPHEN CEO | 2020-05-13 | Option exercise · Stock Option (Right to Buy) | −111,458 | 188,542 | D | ||
| DAVIS STEPHEN CEO | 2020-05-14 | Option exercise · Stock Option (Right to Buy) | −88,542 | 100,000 | D | ||
| Open-market sales · 200,000 sh · avg $46.02 · $9,204,692 | |||||||
Loading xslF345X03/doc4.xml…